The SOL-1 Phase 3 superiority data is the key catalyst to watch at CTS 2026 (June 12-13). Positive efficacy or safety differentiation could drive upside given the 94% bullish analyst consensus and the early-stage biotech stage of Ocular. The HELIOS program update in NPDR may expand the addressable market thesis.
OCUL drugs
OCUL drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 4 $8.80entry
- T+1 · 6mo ago −6.25%α −3.65% · $8.25
- T+5 · 5mo ago −1.14%α +1.42% · $8.70
- T+20 · 4mo ago +9.55%α +10.92% · $9.64
- T+60 · 3mo ago +17.73%α +15.85% · $10.36
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Ocular Therapeutix announced its participation at Clinical Trials at the Summit 2026, where it will present multiple data updates on AXPAXLI (OTX-TKI) including results from the SOL-1 Phase 3 superiority trial in wet AMD and a HELIOS program update in NPDR. The conference presentations are scheduled for June 12-13, 2026, in Las Vegas, with a CEO fireside chat and several clinical sessions.
Key Facts
- SOL-1 Phase 3 superiority trial efficacy outcomes with OTX-TKI in neovascular AMD to be presented at CTS 2026 on June 13
- HELIOS program update on OTX-TKI in nonproliferative diabetic retinopathy (NPDR) also scheduled for June 13
- Safety and tolerability profile of OTX-TKI in neovascular AMD presented separately on the same day
- Pravin U. Dugel, MD (CEO) participating in fireside chat 'From Global KOL to CEO' and panel 'From Innovation to Approval'
- AXPAXLI (OTX-TKI) is an axitinib intravitreal hydrogel based on ELUTYX bioresorbable hydrogel technology, currently in Phase 3 for wet AMD and diabetic retinal disease
Financial Impact
No financial data disclosed; presentations focus on clinical trial results for AXPAXLI. Positive SOL-1 data could support regulatory filings and enhance pipeline value for a $1.8B market cap biotech.
Risk Factors
- SOL-1 Phase 3 data may fail to show superiority vs. existing anti-VEGF standard of care
- Competitive pressure from faricimab and other long-acting agents in wet AMD
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3306630 |
Track record
20 reports on OCUL
4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +24.88% at T+20 after the Aug 3, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 10, 20266d ago 3 Neutral 2/10 Entry $6.66 Now $6.01 −9.76% settles Nov 18
- Nov 9, 20267d ago 8-K Neutral 2/10 Entry $6.85 to $6.01 Now $6.01 −12.26% ▼ −12.26% −10.57% vs SPY
- Nov 9, 20267d ago Press Release Bearish 5/10 Entry $6.85 to $6.01 Now $6.01 +12.26% ▲ +12.26% +10.57% vs SPY
- Nov 5, 202611d ago 144 Neutral 3/10 Entry $6.60 to $6.21 Now $6.01 −8.87% ▼ −5.84% −8.43% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $6.29 to $6.47 Now $6.01 −4.45% ▲ +2.86% +3.01% vs SPY
- Oct 8, 20265w ago 144 Neutral 2/10 Entry $7.54 to $6.87 Now $6.01 −20.29% ▼ −8.89% −6.92% vs SPY
- Sep 2, 202610w ago Insider Cluster Neutral 4/10 Entry $10.64 to $10.49 Now $6.01 −43.52% ▼ −1.41% −0.26% vs SPY
- Aug 26, 202611w ago Insider Cluster Neutral 3/10 Entry $10.82 to $10.64 Now $6.01 −44.45% ▼ −1.66% −1.93% vs SPY
- Aug 3, 202615w ago 8-K Bullish 7/10 Entry $8.40 to $9.24 Now $6.01 −28.45% ▲ +10.00% +7.97% vs SPY
- Jun 17, 202621w ago Press Release Bullish 6/10 Entry $9.64 to $9.85 Now $6.01 −37.66% ▲ +2.18% +3.22% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers